Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James Chih‐Hsin Yang(National Taiwan University Hospital), Lecia V. Sequist(Massachusetts General Hospital), Sarayut Lucien Geater(Prince of Songkla University), Chun-Ming Tsai(Taipei Veterans General Hospital), Tony Mok(Chinese University of Hong Kong), Martin Schüler(University Hospital Heidelberg), Nobuyuki Yamamoto(Wakayama Medical University), Chong‐Jen Yu(National Taiwan University Hospital), Sai‐Hong Ignatius Ou(University of California, Irvine), Caicun Zhou(Shanghai Pulmonary Hospital), Daniel Massey(Boehringer Ingelheim (United Kingdom)), Victoria Zazulina(Bracknell and Wokingham College), Yi‐Long Wu(Guangdong General Hospital)
The Lancet Oncology
June 5, 2015
10.1016/s1470-2045(15)00026-1
Cited by 979

Abstract

Related Papers

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al.|New England Journal of Medicine|2004|11.5k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al.|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, Radj Gervais et al.|The Lancet Oncology|2012|5.5k
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
William Pao, Vincent A. Miller, Katerina Politi et al.|PLoS Medicine|2005|3.5k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto et al.|Journal of Clinical Oncology|2013|3.2k